Celldex Therapeutics Company Insiders
| CLDX Stock | USD 27.23 0.21 0.77% |
Slightly above 80 percent of Celldex Therapeutics' insiders are selling. The analysis of the overall insider sentiment regarding Celldex Therapeutics suggests that a fairly large number of insiders are terrified. Celldex Therapeutics employs about 160 people. The company is managed by 13 executives with a total tenure of roughly 44 years, averaging almost 3.0 years of service per executive, having 12.31 employees per reported executive.
| Sam Martin President CFO, Senior Vice President |
| Sarah Cavanaugh President Vice President Investor Relations & Corporate Communications |
Celldex Therapeutics' Insider Buying Vs Selling
20
Selling | Buying |
Latest Trades
| 2024-11-11 | Anthony S Marucci | Acquired 11500 @ 26.82 | View | ||
| 2024-06-14 | Samuel Bates Martin | Disposed 17172 @ 35.42 | View | ||
| 2024-06-07 | Elizabeth Crowley | Disposed 15000 @ 35.06 | View | ||
| 2024-06-03 | Richard M Wright | Disposed 46844 @ 33.72 | View | ||
| 2024-05-30 | Samuel Bates Martin | Disposed 35000 @ 34.05 | View |
Monitoring Celldex Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Celldex |
Celldex Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Celldex Therapeutics' future performance. Based on our forecasts, it is anticipated that Celldex will maintain a workforce of slightly above 160 employees by January 2025.Celldex Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1973) % which means that it has lost $0.1973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2984) %, meaning that it created substantial loss on money invested by shareholders. Celldex Therapeutics' management efficiency ratios could be used to measure how well Celldex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Celldex Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 453.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 31 M in 2024.Common Stock Shares Outstanding is likely to rise to about 50.9 M in 2024, whereas Net Loss is likely to drop (106.1 M) in 2024.
Celldex Therapeutics Workforce Comparison
Celldex Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 5,302. Celldex Therapeutics holds roughly 160 in number of employees claiming about 3% of equities under Health Care industry.
Celldex Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celldex Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celldex Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Celldex Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.0 | 1 | 1 | 11,500 | 10,500 |
| 2024-06-01 | 1.1818 | 39 | 33 | 1,435,359 | 705,919 |
| 2024-03-01 | 1.0 | 3 | 3 | 34,916 | 34,916 |
| 2022-12-01 | 0.5 | 1 | 2 | 16,860 | 33,720 |
| 2022-09-01 | 0.3889 | 7 | 18 | 204,000 | 398,819 |
| 2021-12-01 | 0.4815 | 13 | 27 | 45,634 | 93,397 |
| 2021-09-01 | 0.8333 | 5 | 6 | 35,348 | 37,656 |
| 2020-12-01 | 0.6667 | 2 | 3 | 20,832 | 30,207 |
| 2018-09-01 | 0.3333 | 1 | 3 | 40,000 | 8,439 |
| 2018-06-01 | 5.3333 | 16 | 3 | 3,670,500 | 9,005 |
| 2017-12-01 | 0.3333 | 1 | 3 | 75,000 | 9,636 |
| 2017-06-01 | 2.4444 | 22 | 9 | 1,259,000 | 113,107 |
| 2017-03-01 | 0.5 | 1 | 2 | 8,000 | 32,927 |
| 2016-12-01 | 2.0 | 2 | 1 | 83,000 | 0.00 |
| 2016-09-01 | 0.2222 | 2 | 9 | 13,000 | 292,000 |
| 2016-06-01 | 10.0 | 20 | 2 | 1,243,847 | 22,847 |
| 2016-03-01 | 1.0 | 1 | 1 | 15,000 | 15,000 |
| 2015-12-01 | 0.5 | 1 | 2 | 25,000 | 50,000 |
| 2015-09-01 | 1.3333 | 8 | 6 | 35,800 | 142,500 |
| 2015-06-01 | 9.0 | 18 | 2 | 822,800 | 50,000 |
| 2014-09-01 | 1.0 | 1 | 1 | 10,000 | 10,000 |
| 2013-12-01 | 0.4444 | 4 | 9 | 236,517 | 473,034 |
| 2009-12-01 | 9.0 | 27 | 3 | 67,000 | 224,461 |
| 2008-09-01 | 1.0 | 7 | 7 | 84,000 | 124,742 |
| 2008-03-01 | 2.1667 | 13 | 6 | 947,019 | 764,796 |
| 2007-03-01 | 7.0 | 7 | 1 | 182,000 | 0.00 |
| 2006-06-01 | 8.0 | 8 | 1 | 74,000 | 4,000 |
| 2005-12-01 | 3.0 | 3 | 1 | 45,000 | 5,000 |
| 2005-09-01 | 4.0 | 4 | 1 | 201,500 | 200,000 |
| 2005-06-01 | 5.0 | 5 | 1 | 50,000 | 50,000 |
| 2004-12-01 | 4.0 | 4 | 1 | 401,500 | 10,000 |
| 2004-06-01 | 1.1 | 11 | 10 | 81,100 | 51,100 |
| 2004-03-01 | 2.5 | 10 | 4 | 739,782 | 737,282 |
Celldex Therapeutics Notable Stakeholders
A Celldex Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Celldex Therapeutics often face trade-offs trying to please all of them. Celldex Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Celldex Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Tibor Keler | Founder, Chief Scientific Officer and Executive VP | Profile | |
| Sam Martin | CFO, Senior Vice President | Profile | |
| Sarah Cavanaugh | Vice President Investor Relations & Corporate Communications | Profile | |
| Elizabeth Crowley | Senior Vice President Chief Product Development Officer | Profile | |
| Sam CPA | CFO, VP | Profile | |
| Ronald Pepin | Chief Bus. Officer and Sr. VP | Profile | |
| Richard Wright | Chief VP | Profile | |
| Patrick Till | Senior Communications | Profile | |
| Prof Schlessinger | CoFounder Board | Profile | |
| Diane MD | Senior Officer | Profile | |
| Margo MD | Senior Affairs | Profile | |
| Freddy Esq | Senior Counsel | Profile | |
| Anthony MBA | President, Founder | Profile |
About Celldex Therapeutics Management Performance
The success or failure of an entity such as Celldex Therapeutics often depends on how effective the management is. Celldex Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Celldex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Celldex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.36) | (0.37) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.33) | (0.35) |
Please note, the imprecision that can be found in Celldex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Celldex Therapeutics. Check Celldex Therapeutics' Beneish M Score to see the likelihood of Celldex Therapeutics' management manipulating its earnings.
Celldex Therapeutics Workforce Analysis
Traditionally, organizations such as Celldex Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Celldex Therapeutics within its industry.Celldex Therapeutics Manpower Efficiency
Return on Celldex Therapeutics Manpower
| Revenue Per Employee | 43K | |
| Revenue Per Executive | 529.5K | |
| Net Loss Per Employee | 883.9K | |
| Net Loss Per Executive | 10.9M | |
| Working Capital Per Employee | 2.5M | |
| Working Capital Per Executive | 30.8M |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.